Royal Bank of Canada
BTTX

Royal Bank of Canada’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Royal Bank of Canada’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-584
Closed – – 7819
2023
Q4 		$0 Buy
584
+390
+201% +$85 ﹤0.01% 7779
2023
Q3 		$0 Hold
194
– – ﹤0.01% 7809
2023
Q2 		$0 Buy
+194
New +$188 ﹤0.01% 7824
2022
Q4 		– Sell
-133
Closed – – 7924
2022
Q3 		$0 Buy
+133
New +$243 ﹤0.01% 8038

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Royal Bank of Canada's BTTX Position: Q1 2024 in Review

Royal Bank of Canada sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 584 shares.

Royal Bank of Canada first reported a position in BTTX in Q3 2022 and held it in 4 quarters. The position peaked at $0 in Q4 2023. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Royal Bank of Canada reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 584 Better Therapeutics, Inc. Common Stock shares in Q1 2024.
  • Royal Bank of Canada first reported a position in Better Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Royal Bank of Canada's Better Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.